Merck ends development of Covid drug it acquired from OncoImmune_老虎社区_美港股上老虎

Merck ends development of Covid drug it acquired from OncoImmune

cnbc2021-04-15

KEY POINTS Merck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune. Merck disclosed in February that U.S. regulators had asked ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Luchella
·2021-04-16
Nice
回复
点赞
举报
云吞面加咖喱
·2021-04-15
Good
回复
点赞
举报
云吞面加咖喱
·2021-04-15
Wow
回复
点赞
举报
albert77
·2021-04-15
Nice
回复
1
举报
收起
- jaywai:
  Nice
  2021-04-15
  回复
  举报
Bodoh
·2021-04-15
What’s the write off?!
回复
点赞
举报
jimzephyr
·2021-04-15
Interesting
回复
1
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1183968578?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-04-15 19:48","share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","id":"1183968578","market":"us","top_or_hot":-1,"title":"Merck ends development of Covid drug it acquired from OncoImmune","media":"cnbc","content":"<div>\n<p>KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html\">网页链接</a>\n\n</div>\n","source":"cnbc_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck ends development of Covid drug it acquired from OncoImmune</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck ends development of Covid drug it acquired from OncoImmune\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 19:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html","article_id":"1183968578","we_media_id":null,"thumbnails":[],"rights":{"source":"cnbc_highlight","url":"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.ArticleHeader-headline{#titleStyle#}a{#lv2TextColor#}.ArticleHeader-time, .Author-authorNameAndSocial a{#sourceStyle#;}","selectors":".PageBuilder-pageWrapper","filters":".ArticleHeader-eyebrow, .RelatedTags-relatedTags","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=1183968578","pubTimestamp":1618487325,"columns":[],"sourceInfo":{"source_id":"cnbc_highlight","name":"CNBC"},"weMediaInfo":null,"summary":"KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from","collect":0,"end_time":0,"defaultTopTitle":"cnbc.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东"},"translate_title":"默沙东结束了从肿瘤免疫公司获得的Covid药物的开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.9},"content_text":"KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked for more data on the drug to support a potential emergency use authorization.\nDue to \"regulatory uncertainties\" and the time and resources needed to provide the additional data, Merck said it decided to discontinue the development of the drug.\n\nMerckannounced Thursday it will end the development of its experimental drug for patients hospitalized with severe Covid-19 after the Food and Drug Administration asked the company to provide additional data to support an emergency use authorization.\nNew Jersey-based Merck acquired the drug, MK-7110, through its $425 million acquisition of privately held biopharmaceutical company OncoImmune late last year.\nAn interim analysis of clinical trial data suggested the drug improved the chances of recovery for the sickest patients with Covid-19 and reduced the risk of death or respiratory failure.\nHowever, Merck disclosed in February that U.S. regulators had asked for more data on the drug beyond the phase three trial already conducted. At the time, the company said it no longer expected to supply the U.S. with the drug in the first half of 2021.\nNow, due to “regulatory uncertainties” and the time and resources needed to provide the additional data, Merck said it decided to discontinue the development of the drug and instead focus its efforts on advancing its other Covid-19 drug as well as accelerating production of the Johnson & Johnson vaccine.\n“Based on the additional research that would be required – new clinical trials as well as research related to manufacturing at scale – MK-7110 would not be expected to become available until the first half of 2022,” the company said in a press release.\nThe announcement marks another disappointment for Merck in efforts to combat the pandemic.\nIn January, it announced it wouldend the development of its two Covid-19 vaccines. In early trials, both vaccines generated immune responses that were inferior to those seen in people who had recovered from Covid-19 as well as those reported for other vaccines, according to the company.\nWhile Merck is discontinuing MK-7110, the company said it will move forward with its oral antiviral drug, molnupiravir, in a phase three clinical trial testing non-hospitalized patients with Covid-19.\n“We continue to make progress in the clinical development of our antiviral candidate molnupiravir,” Roy Baynes, Merck’s chief medical officer, said in a release. “Data from the dose-finding portion of these studies are consistent with the mechanism of action and provide meaningful evidence for the antiviral potential of the 800 mg dose.”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":347543316,"gmtCreate":1618504183435,"gmtModify":1634292444741,"author":{"id":"3580770746236360","authorId":"3580770746236360","name":"Luchella","avatar":"https://static.tigerbbs.com/87eb642775f44f3fd255be4c26cddc59","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3580770746236360","authorIdStr":"3580770746236360"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347543316","repostId":1183968578,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":347238063,"gmtCreate":1618496117652,"gmtModify":1634292528624,"author":{"id":"3575073750684504","authorId":"3575073750684504","name":"云吞面加咖喱","avatar":"https://static.tigerbbs.com/6d130edc8d13c6c564965a9a8d13dd60","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3575073750684504","authorIdStr":"3575073750684504"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347238063","repostId":1183968578,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":347233979,"gmtCreate":1618496042691,"gmtModify":1634292530290,"author":{"id":"3575073750684504","authorId":"3575073750684504","name":"云吞面加咖喱","avatar":"https://static.tigerbbs.com/6d130edc8d13c6c564965a9a8d13dd60","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3575073750684504","authorIdStr":"3575073750684504"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347233979","repostId":1183968578,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":347848657,"gmtCreate":1618488923579,"gmtModify":1634292610371,"author":{"id":"3575421087208890","authorId":"3575421087208890","name":"albert77","avatar":"https://static.tigerbbs.com/23ad8bf74e09800b779350089d72b84f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575421087208890","authorIdStr":"3575421087208890"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/347848657","repostId":1183968578,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4043631,"gmtCreate":1618488989943,"gmtModify":1635738390796,"authorId":3571310539793592,"author":{"id":3571310539793592,"idStr":"3571310539793592","authorId":3571310539793592,"name":"jaywai","avatar":"https://static.tigerbbs.com/b851b00626e38b8250dc613340335154","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347848657,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"EN"},{"id":347849563,"gmtCreate":1618488788052,"gmtModify":1634292611683,"author":{"id":"3559859558754319","authorId":"3559859558754319","name":"Bodoh","avatar":"https://static.tigerbbs.com/349218ea2852130ca86ce660b4aa2d59","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3559859558754319","authorIdStr":"3559859558754319"},"htmlText":"What’s the write off?!","listText":"What’s the write off?!","text":"What’s the write off?!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347849563","repostId":1183968578,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":347851905,"gmtCreate":1618487902807,"gmtModify":1634292616907,"author":{"id":"3567332724919443","authorId":"3567332724919443","name":"jimzephyr","avatar":"https://static.tigerbbs.com/0e06fb235e0a39bae550fa602632b2bb","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3567332724919443","authorIdStr":"3567332724919443"},"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347851905","repostId":1183968578,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":13,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}